Article

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR- mutated metastatic Non-Small Cell Lung Cancer

2024-03-07

Abstract excerpt

<title>Abstract</title> <p>Cobas EGFR mutation Test v2 was FDA-approved as qualitative liquid biopsy for actionable EGFR variants in non-small cell lung cancer (NSCLC). It generates semiquantitative index (SQI) values that correlate with mutant allele levels, but decision thresholds for clinical use in NSCLC surveillance are lacking. We conducted long-term ctDNA monitoring in 20 subjects with EGFR-mutated NSCLC;...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2b201dd8-38bf-553e-ac67-bc40dbe5ea08
DOI: 10.21203/rs.3.rs-3970251/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR- mutated metastatic Non-Small Cell Lung CancerDOI 10.21203/rs.3.rs-3970251/v1Read

Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer.Semantic proximity Read

Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Semantic proximity Read

A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancerSemantic proximity Read

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read

EGFR detection by liquid biopsy: ripe for clinical usage.Semantic proximity Read

The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.Semantic proximity Read

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.Semantic proximity Read

A Radio-Genomics Biomarker for Precision Epidermal Growth Factor Receptor Mutation Targeting Therapy in Non-Small Cell Lung CancerSemantic proximity Read

Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non-Small Cell Lung Cancer.Semantic proximity Read

Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.Semantic proximity Read

Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study.Semantic proximity Read

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.Semantic proximity Read